Phase 1/2 Study of Docetaxel, CDDP and 5-FU therapy in Patients With Unresectable or Recurrent Esophageal Cancer
Not Applicable
- Conditions
- nresectable or recurrent esophageal cancer
- Registration Number
- JPRN-UMIN000003633
- Lead Sponsor
- Department of Surgery, Graduate School of Medicine, Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients have serious complications (heart disease, pulmonary fibrosis, interstitial pneumonia, hemorrhagic tendency and so on) 2. active infection 3. active synchronous malignancy 4. peripheral neuropathy or edema >= Grade 2 (CTCAE version3) 5. history of serious drug hypersensitivity 6. brain metastasis 7. pregnant or lactation women, or women with the possibility of the pregnancy and men who want let to pregnancy 8. patients who are judged inappropriate for the entry into study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recommended dose Dose limiting toxicity Response rate
- Secondary Outcome Measures
Name Time Method Toxicity Time to progression Overall survival